Oxidative stress in Alzheimer's disease: Primary villain or physiological by-product?

References

• Alzheimer's Disease International. World Alzheimer Report 2010. London; 2009.
   Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353–6.
   PubMed Web of Science ®Google Scholar
• Golde TE, Schneider LS, Koo EH. Anti-abeta therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 2011;69(2):203–13.
   PubMed Web of Science ®Google Scholar
• Swerdlow RH. Alzheimer's disease pathologic cascades: who comes first, what drives what. Neurotox Res 2012;22(3):182–94.
   PubMed Web of Science ®Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939–44.
   PubMed Web of Science ®Google Scholar
• McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR , Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):263–9.
   PubMed Web of Science ®Google Scholar
• Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 2006;63(7):936–9.
   PubMedGoogle Scholar
• Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):280–92.
   PubMed Web of Science ®Google Scholar
• Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):270–9.
   PubMed Web of Science ®Google Scholar
• Haroutunian V, Hoffman LB, Beeri MS. Is there a neuropathology difference between mild cognitive impairment and dementia? Dialogues Clin Neurosc 2009;11(2):171–9.
   PubMedGoogle Scholar
• Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82(4):239–59.
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Mielke ML, Gomez-Isla T, Betensky RA, Growdon JH, Frosch MP, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol 2011;179(3):1373–84.
   PubMed Web of Science ®Google Scholar
• Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 1984;122(3):1131–5.
   PubMed Web of Science ®Google Scholar
• Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325(6106):733–6.
   PubMed Web of Science ®Google Scholar
• Seidl R, Cairns N, Lubec G. The brain in Down syndrome. J Neural Transm Suppl 2001;61:247–61.
   PubMedGoogle Scholar
• Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet 2006;38(1):24–6.
   PubMed Web of Science ®Google Scholar
• Haass C, Kaether C, Thinakaran G, Sisodia S. Trafficking and proteolytic processing of APP. Cold Spring Harbor Perspect Med 2012;2(5):a006270.
   PubMed Web of Science ®Google Scholar
• Bero AW, Yan P, Roh JH, Cirrito JR, Stewart FR, Raichle ME, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 2011;14(6):750–6.
   PubMed Web of Science ®Google Scholar
• LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci 2007;8(7):499–509.
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256(5054):184–5.
   PubMed Web of Science ®Google Scholar
• Shankar GM, Walsh DM. Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener 2009;4:48.
   PubMedGoogle Scholar
• von Bernhardi R, Eugenin J. Alzheimer's disease: redox dysregulation as a common denominator for diverse pathogenic mechanisms. Antioxid Redox Signal 2012;16(9):974–1031.
   PubMed Web of Science ®Google Scholar
• Bishop A, Anderson JE. NO signaling in the CNS: from the physiological to the pathological. Toxicology 2005;208(2):193–205.
   PubMed Web of Science ®Google Scholar
• Greenough MA, Camakaris J, Bush AI. Metal dyshomeostasis and oxidative stress in Alzheimer's disease. Neurochem Int 2013;62(5):540–55.
   PubMed Web of Science ®Google Scholar
• Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999;58(4):376–88.
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18(4):351–7.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. The pathological process underlying Alzheimer's disease in individuals under thirty. Acta Neuropathol 2011;121(2):171–81.
   PubMed Web of Science ®Google Scholar
• Marcinek DJ, Schenkman KA, Ciesielski WA, Lee D, Conley KE. Reduced mitochondrial coupling in vivo alters cellular energetics in aged mouse skeletal muscle. J Physiol 2005;569(Pt 2):467–73.
   PubMed Web of Science ®Google Scholar
• Jones DP. Extracellular redox state: refining the definition of oxidative stress in aging. Rejuvenation Research 2006;9(2):169–81.
   PubMed Web of Science ®Google Scholar
• Kowald A. The mitochondrial theory of aging. Biol Signals Recept 2001;10(3–4):162–75.
   PubMedGoogle Scholar
• Eckert GP, Schiborr C, Hagl S, Abdel-Kader R, Muller WE, Rimbach G, et al. Curcumin prevents mitochondrial dysfunction in the brain of the senescence-accelerated mouse-prone 8. Neurochem Int 2013;62(5):595–602.
   PubMed Web of Science ®Google Scholar
• Good PF, Werner P, Hsu A, Olanow CW, Perl DP. Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996;149(1):21–8.
   PubMed Web of Science ®Google Scholar
• Stadtman ER, Levine RL. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003;25(3–4):207–18.
   PubMed Web of Science ®Google Scholar
• Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 1997;23(1):134–47.
   PubMed Web of Science ®Google Scholar
• Nunomura A, Honda K, Takeda A, Hirai K, Zhu X, Smith MA, et al. Oxidative damage to RNA in neurodegenerative diseases. J Biomed Biotechnol 2006;2006(3):82323.
   PubMedGoogle Scholar
• Sultana R, Butterfield DA. Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis 2010;19(1):341–53.
   PubMed Web of Science ®Google Scholar
• Li Z, Wu J, Deleo CJ. RNA damage and surveillance under oxidative stress. IUBMB Life 2006;58(10):581–8.
   PubMed Web of Science ®Google Scholar
• Reed TT. Lipid peroxidation and neurodegenerative disease. Free Radic Biol Med 2011;51(7):1302–19.
   PubMed Web of Science ®Google Scholar
• Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 2006;27(8):1094–9.
   PubMed Web of Science ®Google Scholar
• Mosconi L, Glodzik L, Mistur R, McHugh P, Rich KE, Javier E, et al. Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biol Psychiatry 2010;68(10):913–21.
   PubMed Web of Science ®Google Scholar
• Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 1994;91(8):3270–4.
   PubMed Web of Science ®Google Scholar
• Butterfield DA. Amyloid beta-peptide (1–42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 2002;36(12):1307–13.
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Bush AI. Alzheimer's amyloid beta-peptide (1–42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging 2004;25(5):563–8.
   PubMed Web of Science ®Google Scholar
• Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 1998;785(2):195–206.
   PubMed Web of Science ®Google Scholar
• Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Ann Rev Physiol 1995;57:683–706.
   PubMed Web of Science ®Google Scholar
• Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, et al. Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 2009;106(47):20057–62.
   PubMed Web of Science ®Google Scholar
• Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, et al. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 2002;161(5):1869–79.
   PubMed Web of Science ®Google Scholar
• Borger E, Aitken L, Muirhead KE, Allen ZE, Ainge JA, Conway SJ, et al. Mitochondrial beta-amyloid in Alzheimer's disease. Biochem Soc Trans 2011;39(4):868–73.
   PubMedGoogle Scholar
• Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, et al. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999;274(52):37111–6.
   PubMed Web of Science ®Google Scholar
• Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, et al. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 2001;30(4):447–50.
   PubMed Web of Science ®Google Scholar
• Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM. Iron, zinc and copper in the Alzheimer's disease brain: a quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol 2011;94(3):296–306.
   PubMed Web of Science ®Google Scholar
• Moreira PI, Sayre LM, Zhu X, Nunomura A, Smith MA, Perry G. Detection and localization of markers of oxidative stress by in situ methods: application in the study of Alzheimer disease. Methods Mol Biol 2010;610:419–34.
   PubMedGoogle Scholar
• Vile GF, Tyrrell RM. Oxidative stress resulting from ultraviolet A irradiation of human skin fibroblasts leads to a heme oxygenase-dependent increase in ferritin. J Biol Chem 1993;268(20):14678–81.
   PubMed Web of Science ®Google Scholar
• Kumar S, Bandyopadhyay U. Free heme toxicity and its detoxification systems in human. Toxicol Lett 2005;157(3):175–88.
   PubMed Web of Science ®Google Scholar
• Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, et al. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 1994;145(1):42–7.
   PubMed Web of Science ®Google Scholar
• Ayton S, Lei P, Bush AI. Metallostasis in Alzheimer's disease. Free Radic Biol Med. 2012 Nov 9. pii: S0891-5849(12)01800-X. doi: 10.1016/j.freeradbiomed.2012.10.558. [Epub ahead of print].
   PubMedGoogle Scholar
• Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002;277(47):45518–28.
   PubMed Web of Science ®Google Scholar
• Acevedo KM, Hung YH, Dalziel AH, Li QX, Laughton K, Wikhe K, et al. Copper promotes the trafficking of the amyloid precursor protein. J Biol Chem 2011;286(10):8252–62.
   PubMed Web of Science ®Google Scholar
• Avramovich-Tirosh Y, Amit T, Bar-Am O, Weinreb O, Youdim MB. Physiological and pathological aspects of Abeta in iron homeostasis via 5′UTR in the APP mRNA and the therapeutic use of iron-chelators. BMC Neurosci 2008;9 (Suppl 2):S2.
   PubMedGoogle Scholar
• Karelson E, Bogdanovic N, Garlind A, Winblad B, Zilmer K, Kullisaar T, et al. The cerebrocortical areas in normal brain aging and in Alzheimer's disease: noticeable differences in the lipid peroxidation level and in antioxidant defense. Neurochem Res 2001;26(4):353–61.
   PubMed Web of Science ®Google Scholar
• Ramassamy C, Averill D, Beffert U, Bastianetto S, Theroux L, Lussier-Cacan S, et al. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med 1999;27(5–6):544–53.
   PubMed Web of Science ®Google Scholar
• Ansari MA, Scheff SW. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 2010;69(2):155–67.
   PubMed Web of Science ®Google Scholar
• Omar RA, Chyan YJ, Andorn AC, Poeggeler B, Robakis NK, Pappolla MA. Increased expression but reduced activity of antioxidant enzymes in Alzheimer's disease. J Alzheimers Dis 1999;1(3):139–45.
   PubMedGoogle Scholar
• Schuessel K, Leutner S, Cairns NJ, Muller WE, Eckert A. Impact of gender on upregulation of antioxidant defence mechanisms in Alzheimer's disease brain. J Neural Transm 2004;111(9):1167–82.
   PubMed Web of Science ®Google Scholar
• Casado A, Encarnacion Lopez-Fernandez M, Concepcion Casado M, de La Torre R. Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res 2008;33(3):450–8.
   PubMed Web of Science ®Google Scholar
• Chen L, Richardson JS, Caldwell JE, Ang LC. Regional brain activity of free radical defense enzymes in autopsy samples from patients with Alzheimer's disease and from nondemented controls. Int J Neurosci 1994;75(1–2):83–90.
   PubMedGoogle Scholar
• Maeda M, Takagi H, Hattori H, Matsuzaki T. Localization of manganese superoxide dismutase in the cerebral cortex and hippocampus of Alzheimer-type senile dementia. Osaka City Med J 1997;43(1):1–5.
   PubMedGoogle Scholar
• Gulesserian T, Seidl R, Hardmeier R, Cairns N, Lubec G. Superoxide dismutase SOD1, encoded on chromosome 21, but not SOD2 is overexpressed in brains of patients with Down syndrome. J Investig Med 2001;49(1):41–6.
   PubMed Web of Science ®Google Scholar
• Busciglio J, Yankner BA. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 1995;378(6559):776–9.
   PubMed Web of Science ®Google Scholar
• Aksenov MY, Aksenova MV, Markesbery WR, Butterfield DA. Amyloid beta-peptide (1–40)-mediated oxidative stress in cultured hippocampal neurons. Protein carbonyl formation, CK BB expression, and the level of Cu, Zn, and Mn SOD mRNA. J Mol Neurosci 1998;10(3):181–92.
   PubMed Web of Science ®Google Scholar
• Mao P, Manczak M, Calkins MJ, Truong Q, Reddy TP, Reddy AP, et al. Mitochondria-targeted catalase reduces abnormal APP processing, amyloid beta production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension. Hum Mol Genet 2012;21(13):2973–90.
   PubMed Web of Science ®Google Scholar
• Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, et al. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 2000;275(26):19439–42.
   PubMed Web of Science ®Google Scholar
• Atwood CS, Obrenovich ME, Liu T, Chan H, Perry G, Smith MA, et al. Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res Brain Res Rev 2003;43(1):1–16.
   PubMedGoogle Scholar
• Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60(8):759–67.
   PubMed Web of Science ®Google Scholar
• Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, et al. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci 1999;893:362–4.
   PubMed Web of Science ®Google Scholar
• Nunomura A, Chiba S, Lippa CF, Cras P, Kalaria RN, Takeda A, et al. Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiol Dis 2004;17(1):108–13.
   PubMed Web of Science ®Google Scholar
• Wataya T, Nunomura A, Smith MA, Siedlak SL, Harris PL, Shimohama S, et al. High molecular weight neurofilament proteins are physiological substrates of adduction by the lipid peroxidation product hydroxynonenal. J Biol Chem 2002;277(7):4644–8.
   PubMed Web of Science ®Google Scholar
• Nunomura A, Tamaoki T, Tanaka K, Motohashi N, Nakamura M, Hayashi T, et al. Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol Dis 2010;37(3):731–7.
   PubMed Web of Science ®Google Scholar
• Nunomura A, Tamaoki T, Motohashi N, Nakamura M, McKeel DW, Tabaton M, et al. The earliest stage of cognitive impairment in transition from normal aging to Alzheimer disease is marked by prominent RNA oxidation in vulnerable neurons. J Neuropathol Exp Neurol 2012;71(3):233–41.
   PubMed Web of Science ®Google Scholar
• Joshi A, Ringman JM, Lee AS, Juarez KO, Mendez MF. Comparison of clinical characteristics between familial and non-familial early onset Alzheimer's disease. J Neurol 2012;259(10):2182–8.
   PubMed Web of Science ®Google Scholar
• Teixeira J, Silva T, Andrade PB, Borges F. Alzheimer Disease and Antioxidant Therapy: how long how far? Curr Med Chem 2013 Jan 28 [Epub ahead of print].
   Google Scholar
• Murakami K, Murata N, Noda Y, Tahara S, Kaneko T, Kinoshita N, et al. SOD1 (copper/zinc superoxide dismutase) deficiency drives amyloid beta protein oligomerization and memory loss in mouse model of Alzheimer disease. J Biol Chem 2011;286(52):44557–68.
   PubMed Web of Science ®Google Scholar
• Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012;69(7):836–41.
   PubMedGoogle Scholar
• Farina N, Isaac MG, Clark AR, Rusted J, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev 2012;11:CD002854.
   PubMed Web of Science ®Google Scholar
• Harrison FE. A critical review of vitamin C for the prevention of age-related cognitive decline and Alzheimer's disease. J Alzheimers Dis 2012;29(4):711–26.
   PubMed Web of Science ®Google Scholar
• Gao HM, Zhou H, Hong JS. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol Sci 2012;33(6):295–303.
   PubMed Web of Science ®Google Scholar
• Loef M, Schrauzer GN, Walach H. Selenium and Alzheimer's disease: a systematic review. J Alzheimers Dis 2011;26(1):81–104.
   PubMed Web of Science ®Google Scholar
• van Eersel J, Ke YD, Liu X, Delerue F, Kril JJ, Gotz J, et al. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci USA 2010;107(31):13888–93.
   PubMed Web of Science ®Google Scholar
• Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60(12):1685–91.
   PubMed Web of Science ®Google Scholar
• Sampson E, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD005380. doi: 10.1002/14651858.CD005380.pub3.
   Web of Science ®Google Scholar
• Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, et al. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis 2010;20(2):509–16.
   PubMed Web of Science ®Google Scholar
• Sampson EL, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's dementia. Cochrane Database Syst Rev 2012;5:CD005380.
   PubMedGoogle Scholar